α5 GABAA Benzodiazepine Modulators for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments to improve cognitive function and address cognitive impairment associated with central nervous system disorders, including age-related cognitive decline, dementia, Alzheimer's Disease, PTSD, schizophrenia, and other conditions, by targeting the α5-containing GABAA receptors.
Innovation Solution
Development of benzodiazepine derivatives that act as positive allosteric modulators of α5-containing GABAA receptors to enhance cognitive function and treat cognitive impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cognitive impairment, then general symptom management is achieved, but specific targeting of α5-containing GABAA receptors to improve cognitive function is not accomplished
Solution Approach 1:
The patent applies local quality by designing benzodiazepine derivatives with specific molecular structures that selectively target α5-containing GABAA receptors. The compounds incorporate particular substituents and structural features (such as specific R groups, ring structures, and functional groups) that enable selective binding to the α5 subunit, thereby achieving localized and specific modulation of this receptor subtype rather than general GABAA receptor activation.
2Reliability
If benzodiazepine derivatives are developed to target α5-containing GABAA receptors, then cognitive function improvement is achieved, but drug development complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of benzodiazepine derivatives, including substituent types, positions, and configurations. The invention explores various R groups, ring structures, and functional group arrangements to optimize receptor binding affinity and selectivity. This structured parameter variation enables the identification of compounds with enhanced cognitive effects while managing development complexity through methodical structural optimization.
Data Source
AI summary
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.